Advancing EXL01 Through Clinical Trials & Mechanistic Discovery to Enable Immune Modulation Across Diseases

  • Sharing updates from EXL01’s active Phase II trials in gastric cancer, NSCLC, hepatocellular carcinoma, Crohn’s disease, and C. difficile infection
  • Present early clinical signals from investigator-led studies, including preliminary data in infection and IBD
  • Highlight EXL01’s NOD2-targeted mechanism enabling immune modulation without gut colonisation